CTMX — CytomX Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $142.89m
- -$31.62m
- $101.21m
- 23
- 25
- 90
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -102 | -32.9 | -116 | -99.3 | -0.569 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 18.5 | 17.4 | 16.6 | 16.7 | 4.87 |
Other Non-Cash Items | |||||
Changes in Working Capital | -59.3 | 18.1 | -22.4 | -30.7 | -62.5 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -140 | 5.26 | -119 | -111 | -56 |
Capital Expenditures | -3.5 | -2.31 | -1.61 | -1.74 | -0.84 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 83.2 | -16.4 | 24.1 | 100 | -150 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 79.7 | -18.7 | 22.5 | 98.3 | -151 |
Financing Cash Flow Items | — | — | — | 0.648 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 1.63 | 16.9 | 110 | 0.648 | 30.2 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -59.2 | 3.43 | 13.7 | -11.9 | -176 |